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Summary 
Background: Inhalation technique and medication adherence are highly important 
for the management of chronic obstructive pulmonary disease (COPD) since they 
are essential pre-requisites for achieving full therapeutic effect in patients. 
Community pharmacists are in the best position to deliver services in these two 
areas.    
Methods: This is a ten-year period review of studies looking into the impact of 
community pharmacists in the management of COPD in relation to: inhalation 
technique and medication adherence in the period from 2005 to 2015.  
Results: Ten studies are included in the review. The studies show that community 
pharmacists’ interventions had a positive impact on improving patients’ inhalation 
technique and adherence to inhaled medications. This was shown in some studies to 
be cost-effective in terms of reducing hospitalisation and severe exacerbation rate. 
Scarcity of studies in this domain is noted through this review.  
Conclusions: This review showed that community pharmacists can have a positive 
impact in the management of COPD especially on inhaler technique education and 
medication adherence. Nevertheless, their role is still not fully recognised in this 
area, thus there is a need for more research. There is also a need for more research 
to identify the optimal frequency for inhaler technique re-checking and education as 
a pre-emptive measure against technique deterioration in patients. The results 
highlight the need for healthcare systems to recognise more the role of community 
pharmacists in COPD management in two critical areas that are still challenging in 
real practice.  
 
Key words 
Community pharmacists; inhaler technique; inhalation technique; Chronic 
Obstructive Pulmonary Disease/ COPD; COPD management; medication 
adherence.  
 
 
Introduction and background 
 
Chronic Obstructive Pulmonary disease (COPD) is a chronic condition characterised 
by airflow limitation that is progressive in nature and partially reversible [1]. Tobacco 
smoking, indoor and outdoor pollution are all risk factors for COPD development [2].  
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One of the main objectives of the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) is to increase awareness of this condition [2]. This is particularly 
important due to the high economic and social burden of COPD on healthcare 
systems worldwide [1, 2]. In the European Union, the estimated cost of COPD to 
healthcare systems (as direct costs only) is 38.6 billion Euros (equivalent to $42.3 
billion); whereas in USA this was found to account to a budget of $29.5 billion as 
direct costs and $20.4 billion as indirect costs [2]. 
 
Inhalation technique (IT) and medication adherence (MA) are two key areas that 
should be looked upon with serious consideration when addressing management of 
COPD patients. IT is the process through which the patient correctly performs a 
number of steps in certain order to obtain the adequate dose out of the inhaler 
device [3]. The importance of IT stems from the fact that inhalation therapy 
represents the main pillar in COPD treatment [4-8]. It is the best treatment strategy 
to ensure delivery of adequate concentrations of the administered drug directly to the 
lungs [3-5, 9-11]. Adherence is defined as the degree by which a patient follows a 
mutually agreed plan including medication and life style changes [12]. According to 
the World Health Organisation (WHO), adherence to therapy in chronic conditions is 
estimated to be only 50% in developed countries and lower in developing countries 
[12].  
Incorrect IT may lead to poor disease control [6]. Some authors argue for poor IT to 
be a form of poor adherence [13], whereas others see that poor adherence can be 
triggered by poor IT, as the latter can result in patient’s dissatisfaction with the 
treatment [3]. This can lead to medication wastage due to prescribing higher doses 
or even additional medications thus increasing the financial burden of the disease on 
healthcare systems [7, 10]. In some studies, around 60% of COPD patients had poor 
adherence to their inhalation therapy [14, 15]. A recent review reported a wide 
variation in adherence rates for asthma and COPD patients ranging from 22% to 
78% [16]. Regarding IT, evidence from Europe shows that up to 50% of patients fail 
to use their inhalers correctly [17]. Whereas, another review highlighted that nearly 
100% of patients perform mistakes in their IT that consequently result in delivering 
an inadequate dose of the inhaled medication [18]. Poor adherence and suboptimal 
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IT can lead to increased healthcare costs and poor health outcomes. Thus, there is a 
need for interventions to improve these two areas. 
The aim of this paper is to provide a review of studies evaluating the impact of 
community pharmacists’ interventions on COPD management focusing mainly on IT 
and MA.  
 
Materials and Methods:  
Search Strategy 
The search strategy included primary and secondary sources. The following 
databases were searched: Medline, Scopus, PubMed, Google scholar, Science 
direct. Key words used in the primary search were: community pharmacy, 
community pharmacists, inhaler technique, inhalation technique, COPD 
management, COPD, medication adherence, respiratory patients. The search was 
limited to articles written in English language and published in the period from 
January 2005 – February 2015. A manual search of reference lists of primary 
sources was done to identify any additional studies meeting the inclusion criteria.  
 
Inclusion and exclusion criteria  
The inclusion criteria for this review were: studies in English language and studies 
with interventions done by community pharmacists (CPs) on COPD patients focusing 
on IT and MA. Studies including COPD and asthma patients together, and 
observational studies involving CPs or those conducted in community pharmacy 
settings were also included. As the last decade has witnessed the implementation of 
community pharmacy medication management services, in many countries, that 
targets patients with LTCs [19-21], this review included only studies published after 
2005. 
The exclusion criteria were; studies not in English language, those published before 
2005, studies involving interventions done by other healthcare professionals (HCPs) 
including clinical pharmacists, studies done by CPs or other HCPs on asthma 
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patients only, studies done by CPs whereby the intervention was not related to IT or 
MA, reviews, meta-analyses and grey literature.  
The excluded studies were as follow: three studies with interventions conducted by 
clinical/ hospital pharmacists on COPD patients, nine studies including both asthma 
and COPD patients where by the interventions were not done by CPs, two 
documents that constituted grey literature, one study in Dutch language, and one 
study with pharmacist-led intervention but focusing on COPD exacerbation 
management with systemic corticosteroids. A study with intervention done by CPs 
was excluded to avoid duplication of data since the data was once published jointly 
with asthma patients and once on COPD patients only. The study pertaining to 
COPD patients exclusively was included in the review. In addition, 69 studies that 
were conducted on asthma patients only either by CPs or other HCPs were excluded 
(Figure 1).  
 
Results 
The search of primary sources identified nine articles that met the inclusion criteria; 
four studies involved COPD and asthma patients and five studies involved COPD 
patients only. Search of secondary sources identified one additional study including 
asthma and COPD patients which was included in the review. Thus ten studies were 
included in this review. Only one study had an intervention involving IT and MA, 
three studies focused on IT specifically, four studies had an intervention which partly 
focused on either IT and/or MA and two studies were non-interventional. The steps 
of the research process for the identification of relevant articles are provided in 
Figure 1.  
The summary of the studies reviewed in this paper is presented in Table 1.  
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FIGURE 1. Selection of the relevant studies included in the review.  
 
Abstracts excluded: 
 Studies pertaining to asthma patients only 
with interventions done either by CPs or other 
HCPs (n= 69) 
n=26 
Sources identified in Medline, Scopus, Google 
Scholar, PubMed, Science Direct  
(n= 95) 
Studies excluded (n= 17): 
 Studies not published as primary 
literature (Grey literature) (n=2) 
 Studies on COPD patients but 
interventions done by clinical 
pharmacists not CPs (n=3). 
 Studies on COPD and asthma patients 
but interventions done by other HCPs 
(n=9).  
 Studies with intervention done by CPs 
focusing on COPD exacerbations only 
(n=1). 
 Studies with intervention done by CPs, 
but not in English language (n=1). 
 Studies with duplicate data (n=1) 
 
 
 
Studies 
accepted (n=9)  
 
Total studies 
accepted and 
included in the 
review (n=10) 
Studies included (n=1): further research in 
reference lists of the resultant accepted 
articles identified one additional study  
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Impact of community pharmacists on the management of COPD: review of evidence 
from Europe 
In England, a recent study has shown that a CP-Led COPD service can have a 
positive, cost effective impact on patients’ outcomes. The study evaluated the effect 
of COPD support service by CPs over six months in 34 pharmacies from four 
pharmacy chains. CPs were provided with a one-day training course about service 
delivery along with distance learning materials before the start of the study. The 
provided service was comprehensive including smoking cessation, education and 
advice about IT and inhaler checking, provision of support and awareness of 
symptoms in case of exacerbations and general life-style advice. Initial consultation 
involved getting baseline data regarding self-reported MA, clinical outcomes, 
National Health Services (NHS) resource utilisation and quality of life (QoL). All 
participants (n=306) had an initial consultation. However, the follow-up frequency 
was not equivalent for all patients. Monthly consultations for all participants should 
equate to 1836 consultations over six months; however only 742 consultations were 
completed. This variation in follow-up cannot be explained by the dropout rate 
reported as 107 patients. Furthermore, usable data for comparison at baseline and 
six months was only available for 137 patients. Several improvements were reported 
in this study but the only improvement that was statistically significant was MA (P 
<0.001). There was a reduction by 0.869 in COPD assessment test (CAT) score over 
the six-month study period but that was not statistically significant (P= 0.078). 
Likewise, a 4.1% reduction in the percentage of smokers in the final sample (n=137) 
was observed which was not statistically significant (P= 0.219). As for QoL, the mean 
change in EQ-5D score was 0.029 between baseline and follow-up (for EQ-5D, 0.03 
is regarded as the minimal important difference [22]). The EQ-5D was used to 
estimate the QALY (quality-adjusted life year) change associated with the 
intervention. Change in QALY was calculated to be 0.008 (95% CI: 0.000 to 0.017) 
after a follow-up period of 201 days. The intervention was reported by the 
researchers to be cost-effective with a mean savings of £87.66 per patient for total 
NHS costs and £94.12 for total societal costs (i.e.: total NHS costs + cost of lost 
productivity). The mean cost-saving associated with the intervention was mainly due 
to the reduction in the use of NHS services notably hospital admissions. However, 
the results should be treated with some caution due to the before-and-after study 
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design, the lack of a comparison control group (CG), and the fact that the 
intervention was conducted in winter period when COPD is expected to be worse in 
comparison to the pre-intervention period [23]. 
 
In Netherlands, a large scale study reported that pharmacist-led interventions can 
improve sub-optimal medication treatment in COPD and asthma patients. The study 
comprised 3757 patients across 107 pharmacies in the intervention arm and 105,507 
patients in the control arm. The intervention consisted of a comprehensive structured 
pharmacy program focusing on: compliance with maintenance therapy, improving IT 
and selection of inhaler devices, and reconsidering the treatment regimen with the 
possibility of stopping any sub-optimal medication. The primary outcome showed an 
absolute reduction in high dose treatment (HDT) with corticosteroids and antibiotics 
by 0.54 (95% CI 0.28-0.86). Secondary outcome measures consisted of changes in 
a list of 19 potential problems indicating sub-optimal treatment that were defined and 
set according to prevailing treatment guidelines. The results indicated that 14 out of 
19 problems were reduced to a higher extent in the intervention group (IG) compared 
with CG. However, only three problems were significantly reduced; the 35% (95% CI 
6-54%) reduction in the use of obsolete medication (acetylcysteine, cromoglicic acid 
or nedocromil), the 61% (95% CI 38-75%) reduction in the use of contra-indicated 
medication (selective beta-blockers) and the 29% (95% CI 13-42%) reduction in the 
use of powder inhalers for patients over 75 due to their insufficient inspiratory flow 
rate. A limitation for this study is self-selection bias for CPs in the intervention arm for 
those pharmacists who were more interested and had better communication skills as 
there was no randomisation strategy employed. Another possible bias would be that 
of patient selection since they were selected by the CPs for the IG [24].  
In Germany, a prospective multi-centre intervention study demonstrated the 
effectiveness of a single intervention done by CPs in improving the quality of IT in 
COPD and asthma patients. The study was conducted on a pre-post comparison 
basis. CPs did not receive any training before the start of the study, but it was 
mandatory for all recruited CPs to already have the certified continuing education 
programme in pharmaceutical care for COPD and asthma patients in Germany. The 
study was based in 55 community pharmacies over three months. 757 patients 
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received a one-time intervention focusing on IT education through providing 
demonstration of the correct steps, practical exercises and verbal instructions at 
baseline according to individual performance. Patients were then required to 
demonstrate the technique again at a follow-up appointment after 4-6 weeks. At 
baseline, 78.9% of study sample had at least one error, however this percentage has 
significantly dropped to 28.3% after the intervention (P <0.001). There was also a 
significant drop in the average number of errors per patient from 2.5 to 0.5 (P < 
0.001). Despite the significance of results, the authors questioned the sustainability 
of this one-time intervention on the long run and argued for the necessity of 
performing such educational interventions on a regular basis. They also highlighted 
that CPs are in the best position to deliver these services. Study limitations were 
related to its short duration and the possibility of selection bias. In addition, the 
authors had no information regarding any possible outside training on IT that might 
have been taken by the patients during the study period [5]. 
 
In Belgium, the study of Mehuys et al.[9] was the first cross-sectional, observational 
study on COPD treatment to be conducted in the community pharmacy setting. The 
study was based in 93 pharmacies and involved 555 COPD patients. Data regarding 
COPD medication, smoking history and vaccination status were collected from 
participants by questionnaires. IT was assessed by checking against device specific 
checklists, whereas adherence was assessed by retrospective analysis of 
prescription refill rates for 12 months. Results showed that management of COPD 
patients in primary care is sub-optimal. Almost half (48%) of the patients had poor 
MA, 40% were smokers, 21% and 3.5% made errors in IT for rescue and control 
medications respectively, and only 65% of patients under 65 had flu vaccination. The 
researchers concluded that CPs can have a potential impact on improving COPD 
management by focusing more on the following four areas: smoking cessation, 
influenza vaccination, MA and IT and proposed this as a hypothesis for future 
testing. 
Interestingly, the study of Tommelein et al.[25] evaluated the hypothesis stated 
above. It was the first randomised controlled trial (RCT) to address the impact of 
CPs’ intervention on IT and MA as primary outcomes in COPD patients in Belgium. 
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This large-scale trial involved 734 COPD patients who were blinded with respect to 
group allocation. The trial lasted for three months; patients were followed up at one 
and three months across 170 community pharmacies. CPs received training about 
COPD pathophysiology and treatment according to GOLD guidelines before the start 
of the trial. The intervention offered by CPs was educational in nature based on 
GOLD guidelines in the form of structured patient education adapted according to 
patients’ needs. The education was offered in written and oral format focusing on 
MA, information about COPD and its treatment, self-management, smoking 
cessation and physical demonstration of IT using a placebo inhaler. The education 
was delivered as one-to-one counselling sessions. Patients in the control arm 
received usual pharmacist care; IT was evaluated using device-specific IT checklists 
designed by the researchers. The study reported a significantly greater improvement 
in IT and MA scores in the IG compared to the CG at the end of the trial [the mean 
estimated difference was 13.5% for IT (95%CI: 10.8-16.1%; P < 0.0001) and 8.51% 
for MA (95%CI: 10.8-16.1%; P < 0.0001)]. The number of patients who made major 
errors in IT (for Metered Dose Inhaler (MDI): failure to remove cap and/or shake the 
MDI; for Dry Powder Inhaler (DPI): failure to load device correctly and/or inhale 
quickly and deeply through device) dropped from 15.6% at baseline to 1.2% after 
three months in the IG, whereas in the CG the drop was from 11.6% to 4.6% (P= 
0.002). Another interesting result in this study was the significant likelihood to obtain 
a 100% inhalation score as a result of the intervention (odds ratio 3.03, 95%CI: 2.12-
4.34; P <0.0001) in comparison to no intervention. Likewise, a significant likelihood 
to obtain more than 80% Medication refill adherence (MRA) scores in the IG in 
comparison to CG (odds ratio: 2.15, 95%CI: 1.46-3.14; P<0.0001). There was also a 
significant reduction in annual hospitalisation rate (P= 0.003) and decrease in the 
annual severe exacerbation rate (P < 0.007) in comparison to the CG. However, 
there was no significant improvement in health status (at three months, P values for 
CAT score and EQ-5D were 0.832 and 0.19 respectively) or smoking status (P= 
0.33) which was attributed to the short study duration. Other limitations include 
selection bias since participation is more likely to involve motivated patients. Another 
source of bias would be that CPs in the study were both doing the educational 
intervention and measuring their own performance. Furthermore, MRA and IT scores 
were only calculated for the principal maintenance drug even if the patient is taking 
more than one inhaled medication [25]. The cost effectiveness analysis of this 
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intervention in the Belgian Healthcare system showed a cost savings of €227 per 
patient (95%CI: €58-€403) in the IG for a one-year time period. Savings were mainly 
generated due to the reduction in exacerbation treatment expenses in the IG 
compared to CG. QALY gain was minimal in this study (<0.001 QALYs) which was 
attributed mainly to reduction in exacerbations [26]. 
In Bulgaria, a RCT was done to assess the effect of educational intervention on QoL 
for COPD patients, forced expiratory volume in one second (FEV1) rate and IT. The 
study involved 30 COPD patients with 15 patients in each group. The intervention 
was delivered by the researchers and five pharmacy students across the 24 private 
community pharmacies that have the highest number of COPD patients. The content 
of education included the following topics: COPD as a disease, medication use, IT, 
adverse drug reactions, symptoms recognition in case of exacerbations and smoking 
cessation. All information was developed by the authors depending on several 
asthma and COPD guidelines. Patients in the IG received the educational 
programme in the form of sessions over a four-month period (one session each 
month). Patients were also given information leaflets after each session. The level of 
knowledge gained throughout the study was assessed at the beginning of the 
second, third and final sessions by conducting direct interviews with patients. 
Patients in the CG were not provided with any information and received usual care 
(i.e.: routine dispensing services). Results showed that only improvement in FEV1 
rate was statistically significant for IG compared to CG (after four months, p< 0.05). 
There was improvement in QoL and IT within the IG itself between baseline and the 
end of the study, but this was not statistically significant when compared to the CG. 
However, the researchers attributed these results to the short duration of the study. 
They also highlighted that such results cannot be generalised in the country due to 
the small sample size [27].  
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Impact of community pharmacists on the management of COPD: review of evidence 
from other developed countries 
In other developed countries such as Canada, a small pilot study was conducted to 
shed the light on the impact of CPs in COPD management.  21 CPs participated in 
the assessment of 59 COPD and 23 asthma patients. All CPs completed a brief 
continuing educational session about COPD and asthma management prior to the 
study. The service offered by CPs included: smoking cessation advice, assessment 
of the patients’ medical condition (medications problems, adherence and disease 
control), checking and rectifying IT and provision of appropriate individualised action 
plan when needed. The results, due to the nature of the study being pilot, were in the 
form of recommendations. 59 recommendations were made by pharmacists to the 
prescribing physicians, including: implementation of patient-customised action plan 
(n=17), change in pharmacotherapy (n= 12), inhaler device change (n= 9) and 
reconsideration of adherence to medications (n=7). Interestingly, the majority of the 
treating physicians reported that the recommendations made were very useful. 
Approximate time required to deliver this service was 30 minutes per patient and 
hence lack of time was identified by CPs as a potential barrier for service delivery 
[28]. 
In New Zealand, a recent study assessed IT among 103 patients (86 with asthma 
and 17 with COPD) in 26 community pharmacies. Prior assessment, the researchers 
received training about the correct IT for all devices available in the country. Almost 
half (around 47%) of the assessments done indicated poor IT. The study also 
included a patient survey about previous IT education and re-assessment. Most of 
the patients (76%) received this education from the doctor, followed by 11% from a 
nurse, 9% from others (parents, internet, leaflets) and only 4% from the pharmacist. 
As for technique re-assessment, 44% of patients had their IT rechecked with only 
1% of them having this done by a pharmacist. This showed that the role of CPs was 
not prominent in IT education and re-assessment. Consequently, the authors 
emphasised the need to reinforce IT education and re-assessment through an 
interdisciplinary approach [4]. 
In Australia, a study by Bosnic-Anticevich et al.[29] was the first one investigating the 
effect of two educational interventions regarding IT in community pharmacy setting. 
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The study included 52 asthma and COPD patients. Unlike other studies, this one 
focused mainly on one type of inhaler which is the pressurised Metered Dose Inhaler 
(pMDI). The two pharmacy student researchers who conducted the assessments 
and interventions were trained about the use of pMDI and the technique 
assessment. The two interventions were randomised as follows: standard instruction 
group (SIG) with patients provided with verbal and written instructions on the pMDI 
technique, and extended instruction group (EIG) where patients received verbal and 
written instructions besides physical demonstration using placebo inhaler. Patients 
were assessed and followed up at baseline and 4, 8 and 16 weeks. In each visit, the 
IT was firstly assessed then the intervention delivered according to the group and 
then re-assessed again, this was repetitive up to three times or until the patient 
showed a correct technique. The study reported improvement in pMDI technique for 
both groups over the study period and showed that the addition of physical 
demonstration to written and verbal instructions is a more effective approach to 
improve IT than written and verbal instructions alone. The SIG showed statistically 
significant increase in IT score from baseline (P <0.05) at the last follow-up visit only; 
whereas this was statistically significant in the EIG at all the follow-up visits (P<0.05 
for each visit). In this study, 86% (45/52) of patients had previous IT education and 
most of them (62%) had it only at the time of first prescription with a mean of 13 
years ago. In a similar manner to the previous study in New Zealand; the role of the 
pharmacist was not prominent since 33% of patients had their IT education by GP, 
29 % by a GP and a pharmacist and only 2% by a pharmacist alone. Among those 
who had previous IT education (n=45): 69% (31/45) had no IT rechecking, 21% 
(9/45) had their IT rechecked by a GP, 6% (3/45) rechecked by a specialist and only 
4% (2/45) rechecked by a pharmacist. This study also highlighted the issue of IT 
deterioration over time. Patients showed continuous improvement in IT in the follow-
up visits that were separated by one-month interval. However, there was a decline in 
IT in the last follow-up visit which was two months after the third visit indicating the 
necessity of repeating instructions in order for patients to maintain the technique.  
The study emphasised the role of CPs in helping patients with correcting and 
maintaining IT over time especially when dispensing the medication. Limitations in 
the study include; the small sample size, interventions and assessments being done 
by the same researchers and the possibility of patients having outside advice about 
IT during the study [29]. 
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In Japan, a long term study significantly demonstrated higher adherence to inhaled 
medications in patients receiving repeated instructions on IT from CPs. The study 
evaluated the four-year effect of a network system which was implemented in 81 
community pharmacies. The system was designed in the form of an educational 
programme to provide correct and consistent IT to COPD patients. Through this 
programme, CPs were trained about COPD, IT for all inhaler devices available and 
adherence to inhaled medications, and were registered as IT instructors upon 
training completion. The service consisted of providing instructions in correct IT via 
lectures, demonstrations and role play. This was offered every six months. Despite 
the small sample size of the study, it demonstrated significant improvement in 
adherence to inhalation therapy (P= 0.024) as well as significant reduction in the 
frequency of exacerbations (P= 0.017) after four years in comparison to baseline 
data. However, there was no significant change with respect to health related quality 
of life (HRQoL) (P= 0.99). The authors attributed the improvement in clinical 
outcomes to the improvement in IT and stressed on the need to provide patients with 
repeated instructions on proper IT at least every six months. The long term design of 
this study gave strength to the results. However, the small sample size, the lack of a 
CG and the fact that the participants at study start and after four years were not 
equivalent because of difficulty of follow-up over a long period constitute the 
limitations of this study. Usable information was only obtained from 55 patients (out 
of 88) at baseline and from 51 patients (out of 82) after four years [8]. 
 
 
 
TABLE 1. Summary of studies included in this review        
15 | P a g e  
 
Study  
 
 
Type of the 
Study  
Study 
location  
Study 
Population  
Type of Intervention 
provided by CPs 
 Findings / Results  Remarks  
Wright et al 
(2015) [23] 
Pre-post 
study 
(Before-and-
after study 
with no CG)  
England  306 initial 
COPD 
patients, final 
cohort is 137 
(with usable 
information) 
Comprehensive COPD 
support service: 
Smoking cessation,  
Symptoms recognition in 
case of exacerbations, 
General life style advice, 
Advice on IT and choice 
of inhaler.  
Improvement in MA 
(P<0.001). 
Reduction of CAT scores.  
Estimated cost savings of 
£87.66 for total NHS costs 
and £94.12 for total societal 
costs per patient. 
Estimated QALY gain of 
0.008. 
 
The high dropout rate 
and the lack of usable 
information (complete 
data) for certain 
patients resulted in 
having 137 patients in 
the final sample out of 
the 306 patients 
initially recruited.  
Ottenbros et 
al (2014)[24] 
Prospective 
cohort study 
with IG and 
CG 
Netherlands  3757 COPD 
and asthma 
patients in the 
IG, 105,507 
patients in the 
CG. 
Comprehensive care 
through structured 
pharmacy care program 
focusing on areas like 
compliance with 
maintenance therapy, 
improving IT and 
selection of inhaler 
devices and 
reconsideration of the 
treatment regimen with 
the possibility of stopping 
any sub-optimal 
medication. 
Reduction in the need of 
oral corticosteroids and 
antibiotics. 
Reduction in medication 
wastage by 35 % for 
obsolete medication and 
61% for contra-indicated 
medication. 
29% reduction in the use of 
DPIs for elderly patients 
(>75 years) 
Additional research is 
needed to estimate 
cost-savings due to 
implementation of 
such beneficial 
interventions.  
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Hammerlein 
et al 
(2011)[5] 
Prospective 
multi-centre 
intervention 
study ( No 
CG) 
Germany  757 COPD 
and asthma 
patients: 380 
asthma, 184 
COPD and 
193 other 
respiratory 
diseases. 
Educational: IT 
education through 
providing demonstration 
of the correct steps in the 
technique, practical 
exercises and verbal 
instructions. 
Reduction in the number of 
patients making errors in IT 
from 78.6% at baseline to 
28.3% after the intervention  
(P < 0.001). 
Drop in average number of 
errors from 2.5 to 0.5/ 
patient (P < 0.001). 
 
25% dropout among 
recruited CPs in the 
study due to lack of 
time, staff shortage, 
illness or difficulties in 
recruiting patients. 
 
Mehuys et al 
(2010)[9] 
Cross-
sectional 
observational 
study (No 
CG) 
Belgium  555 COPD 
patients  
Assessment: via 
administered 
questionnaire to elicit 
personal characteristics, 
influenza vaccination, 
smoking history, COPD 
medication and health 
status.  
Sub-optimal management in 
COPD patients:  
48% of patients with poor 
MA. 
Low flu vaccination status in 
patients under 65 (65%). 
40% of patients were 
smokers. 
21% had IT errors for 
rescue medications 
3.5% had IT errors for 
control medications  
This was the first 
observational study 
on COPD treatment to 
be conducted in the 
community pharmacy 
setting in Belgium. 
Tommelein et 
al (2014) and  
van Boven et 
al (2014) 
[25, 26] 
 
Prospective 
RCT 
Belgium 734 COPD 
patients : 363 
patients in CG 
and 371 
patients in IG 
Educational: structured 
patient education in 
written and oral format 
focusing on MA, 
information about COPD 
and its treatment, self-
management, smoking 
cessation and physical 
demonstration of IT 
using a placebo inhaler. 
Significant improvement in 
IT score (P < 0.0001) and 
MA (P < 0.0001). 
Drop in the number of 
patients making major 
errors in IT by 14.4%.  
Significant reduction in 
hospitalisation rate 
(P=0.003) and decrease in 
the annual severe 
exacerbation rate (P< 
Long term trials are 
needed to confirm 
other outcome 
measures like 
smoking status and 
health status.  
 
This is the first and 
largest RCT to 
address the impact of 
CPs’ intervention on 
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0.007).  
 
Estimated cost savings of 
€227 per patient (95%CI: 
€58-€403) in the IG for one-
year time horizon.  
QALY gain was minimal 
(<0.001 QALYs) and was 
attributed mainly to 
reduction in exacerbations. 
IT and MA in COPD 
patients specifically in 
Belgium.  
Andreevska 
et al (2014) 
[27] 
Prospective 
RCT  
Bulgaria  30 COPD 
patients : 15 
patients in CG 
and 15 
patients in IG 
Educational: structured 
educational programme 
delivered in form of 
monthly sessions 
focusing on appropriate 
use of medication, 
adverse drug reactions, 
information about COPD 
as a disease, IT training, 
COPD exacerbations 
and smoking cessation; 
combined with provision 
of leaflets after each 
session.  
Significant improvement in 
FEV1 rate (p<0.05) only.  
Improvement in IT and QoL 
were not statistically 
significant.  
The authors 
highlighted that COPD 
patients are in 
constant need for 
educational 
programmes in 
community pharmacy 
settings.  
Beauchesne 
et al 
(2012)[28] 
Pilot study 
(No CG) 
Canada  59 COPD and 
23 asthma 
patients 
Assessment intervention 
comprising: smoking 
cessation advice, 
assessment of the 
patient’s medical 
condition in relation to 
medications problems, 
adherence and disease 
control, checking and 
education concerning IT 
and provision of 
59 recommendations were 
provided from CPs to GPs:  
implementation of patient-
customised action plan 
(n=17), change in 
pharmacotherapy (n= 12), 
inhaler device change (n= 
9) and reconsideration of 
adherence to medications 
(n=7) 
Lack of time was 
identified as barrier to 
service delivery for 
CPs.  
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appropriate 
individualised action plan 
when needed. 
Bryant et al 
(2013) [4] 
Cross-
sectional  
study ( No 
CG)  
New 
Zealand 
103 patients: 
17 COPD and 
86 asthma 
patients.  
Assessment of IT among 
patients: via 
administered 
questionnaire to elicit 
personal characteristics 
and IT education 
provider; physical 
demonstration of IT 
using placebo devices. 
47 % of IT assessments 
indicated poor technique.  
Confusion among 
HCPs about who 
should be responsible 
for educating and 
following up patients 
concerning IT may 
result in lack of 
provision for this 
service and 
consequently having 
high rates of poor 
technique among 
patients.  
Bosnic-
Anticevich et 
al (2010) [29] 
Randomised 
controlled 
parallel group 
study ( with 
SIG and EIG) 
Australia  52 patients: 7 
COPD, 1 
Sleep apnea 
and 44 asthma 
patients.  
 
25 patients in 
SIG , 6 
patients 
remained in 
the last follow-
up; and 27 
patients in  
EIG , 18 
patients 
remained in 
the last follow-
up.  
Repeated Assessment 
and Education:  
 SIG: receiving verbal 
and written IT 
instruction 
 EIG: receiving verbal 
and written IT 
instruction with 
physical 
demonstration.  
Significant improvement in 
IT scores in the EIG at the 
four follow-up visits.  
Significant improvement in 
IT scores in the SIG at the 
last follow-up visit only. 
This was the first 
study addressing the 
effect of two 
educational 
interventions 
regarding pMDI 
technique provided 
repeatedly in 
community pharmacy 
setting. 
 
Need of repetition of 
this study with a large 
sample size and for 
longer duration in 
future. 
 
Not perceiving any 
benefits from the 
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study was the main 
reason behind the 
high dropout rate of 
patients in the SIG .   
Takemura et 
al (2013)[8] 
Pre-post, 
non-
equivalent 
group study 
(No CG). 
Japan  88 COPD 
patients 
initially; usable 
information 
obtained from 
55 patients at 
baseline and 
51 patients 
after 4 years. 
Educational: providing 
instructions in correct 
and consistent ITs via 
lectures, demonstration 
and skills training for 
inhalers use and role 
playing every six months 
through an established 
network system 
implemented in 
community pharmacies.  
Significant improvement in 
adherence to inhalation 
therapy (P= 0.024). 
Significant reduction in the 
frequency of exacerbations 
(P= 0.017). 
Further research with 
large sample size is 
needed to confirm the 
validity of this 
established 
educational network 
system in Japan. 
 
Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; IT, Inhalation Technique ; CPs, community pharmacists; CG, control group; IG, 
intervention group; MA, Medication adherence; RCT, randomised controlled trial; GPs, general practitioners; FEV1, forced expiratory volume in 
one second; CAT, COPD Assessment Test; QALY, quality-adjusted life year; DPI, Dry Powder Inhaler; QoL, Quality of Life; HCPs, healthcare 
professionals;  pMDI, pressurised Metered Dose Inhaler; SIG, standard instruction group; EIG, extended instruction group . 
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Discussion: 
This review showed that CPs had a positive impact in relation to IT education and 
MA of COPD patients. Most of the studies reviewed involved educational 
interventions.  With respect to IT, the offered interventions were found to significantly 
reduce IT errors or even improve the choice of the inhaler [5, 23-25, 28, 29]. For MA, 
the review showed that CPs interventions resulted in improving adherence to inhaled 
medications which was statistically significant in the addressed studies [8, 23, 25]. 
This is consistent with other studies which show that pharmacist-delivered 
interventions can lead to significant improvement in medications adherence in other 
diseases [30, 31]. Two studies [23, 25, 26] in this review showed that the provided 
interventions were cost-effective in terms of reducing hospitalisation rate and severe 
exacerbation rate. There was a cost saving of £94.12 per patient (equivalent to 
€133) for six months in Wright et al.[23] study in the UK and €227 per patient for one 
year in Tommelein et al. [25, 26] study in Belgium. This highlights that IT and MA 
interventions provided by CPs are not only beneficial for patients but also for the 
healthcare system. 
 
As seen from this review, there are only a few studies addressing the impact of CPs 
in COPD management. Some case studies which involved CPs were found during 
the literature search but these were not published as primary literature and hence 
could not be used in this review. The scarcity of research in this area can have two 
possible explanations. First, COPD is still underdiagnosed in many countries [32-40]. 
Estimates by the Department of Health in the UK indicate that approximately 2.2 
million people are still undiagnosed [1].This has been corroborated by a recent 
study, which showed that the chances of early diagnosis of COPD by doctors in the 
UK have been missed in 85% of cases in the five years before the actual diagnosis 
[41]. In the USA, 12.7 million people have COPD. However, evidence suggests that 
around 24 million have impaired lung function, indicating that almost half of the 
cases in the USA remain undiagnosed [42]. Second, the potential role of CPs in the 
reduction of medical and economical costs of inappropriate medication use is still not 
well recognised by the public. This can be partly attributed to the top down nature of 
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the health sector; patients usually perceive doctors of higher authority in the medical 
hierarchy in comparison to pharmacists [43]. The call for enhancing the agenda for 
research into the impact of CPs on health has already been raised in the UK [43]. It 
can be argued that this approach should also be followed by other countries given 
the economic burden of COPD on healthcare systems all over the world. 
Nevertheless, it is obvious from the studies reviewed in this paper that evidence 
regarding impact of CPs on COPD management is growing in the literature, since 
most of the studies reviewed were published between 2010 and 2015.  
 
There was a clear emphasis from the reviewed studies on the need to provide 
patients with repeated instructions on correct IT by CPs and not to consider it as a 
one-time service in order to ensure sustainability [5, 8, 29]. The German study [5] in 
this review highlighted that patients benefited from IT education intervention 
irrespective of their previous education. On the other hand, two studies [4, 29] in this 
review showed how the role of CPs in IT education and re-assessment was not 
prominent. There are three possible reasons for this issue. The first reason might be 
the lack of sufficient knowledge and skills by CPs in IT education [44-46]. Several 
studies have shown that HCPs including pharmacists lack the knowledge needed to 
educate patients about correct IT [47-51]. The second reason could be that although 
CPs might be aware of the importance of IT as a concept, yet they might not be fully 
aware of the importance of sustaining the correct IT in patients and the possibility of 
technique deterioration, even if patients have been using their inhalers for years. 
Consequently, CPs overlook the necessity of IT assessment on a routine basis. 
Thus, despite the obvious importance of inhalation therapy as a treatment strategy in 
respiratory conditions, the significance of correct IT gets overlooked [9]. The third 
reason is the lack of clarity within healthcare systems as to which professional has 
responsibility for IT assessment [4, 52] hence pharmacists do not feel accountable 
for it. In fact, previous studies emphasised that HCPs should not make assumptions 
that their patients are being instructed by other colleagues from different disciplines 
about IT and should assure routine education and re-checking of their patients’ IT 
[52, 53].  
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Existing evidence suggests that IT decline over time due to patients forgetting the 
proper instructions [17, 18, 29]. However, there was a disparity between the 
Japanese and the Australian study reviewed about the optimal frequency for IT re-
checking and education. While the Japanese study recommended this to be done 
every six months as a minimum, the Australian study showed that a two-month gap 
period is sufficient to cause decline in IT even with patients using their inhalers for 
years. Interestingly, a previous study has shown the presence of a significant 
positive relationship between the provision of repeated IT instruction and adherence 
(p=0.04) and HRQoL (P=0.017) in COPD patients [54]. However, the frequency of 
repetition was not clearly specified [54]. COPD guidelines such as GOLD emphasise 
the importance of IT re-checking at each visit but with no specific frequency [2]. The 
National Institute for Health and Care Excellence (NICE) guidelines specify the 
frequency as once yearly [55]. Therefore, more research is needed to determine the 
optimal frequency of IT assessment and education to avoid deterioration of IT in 
patients. 
 
Conclusions  
This paper aimed at reviewing studies evaluating CPs’ interventions and their impact 
on COPD management. As seen from this review, there is paucity of studies 
investigating such impact. The reviewed studies revealed that CPs can have a 
positive and cost-effective impact in the management of COPD in relation to MA and 
IT education which in turn can decrease medication wastage, hospital admissions 
and severe COPD exacerbations. However, the role of CPs is still not fully studied or 
recognised, thus there is a clear need for more research. The review also highlighted 
the need for more research to achieve a consensus on the frequency of IT re-
checking and education to prevent technique deterioration. The results highlight the 
need for healthcare systems to recognise more the role of CPs in COPD 
management in two critical areas that are still challenging in real practice.  
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